Angiogenesis is now considered to be crucial for tumor growth and metastasi
s. In several tumors, microvascular density has been shown to be correlated
with metastasis and aggressiveness. Vascular endothelial growth factor (VE
GF) is a secreted endothelial cell-specific mitogen, which is induced by hy
poxia and is angiogenic in vivo. VEGF has bl-en identified in a wide variet
y of malignancies including head and neck squamous cell carcinomas (HNSCC).
We investigated the circulating level of VEGF in sera from patients with v
arious head and neck squamous cell carcinomas (n = 71) as well as from heal
thy normal controls (n = 47). Serum VEGF concentrations were determined as
serum immunoreactivity by using a quantitative sandwich enzyme immunoassay
technique. For statistical analysis, the Wilcoxon 2-sample test and Kruskal
-Wallis test were performed. The majority of the patients with HNSCC were f
ound to have high concentrations of serum VEGF. The levels of VEGF in the s
era of patients with cancer ranged from below the detection limit to 937.1
pg/ml (mean, 144.5 pg/ml). In contrast, the VEGF serum levels in 47 healthy
individuals ranged from below the detection limit to 168.1 pg/ml (mean, 32
.7 pg/ml), VEGF se:rum concentration being significantly higher in HNSCC pa
tients (P = < 0.001). These findings indicate that a positive angiogenesis
regulator;such as VEGF might function as an endocrine growth factor, partic
ularly for solid HNSCC tumors and may be a useful marker for clinical monit
oring.